http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
-
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
-
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug
-
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
-
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
-
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
-
Entera Bio board members purchase shares in open market transactions
-
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
-
Entera Bio names former Pfizer executive as new chairman
-
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
-
OPKO Health and Entera Bio expand partnership for oral PTH tablet
-
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
-
Entera Bio outlines Q1 2026 milestones for osteoporosis drug
-
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
-
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
-
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
-
Entera Bio reports preclinical data for once-daily hypoparathyroidism tablet
-
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
-
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
-
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
-
Entera Bio reports bone density gains in early menopause trial
-
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
-
Entera Bio to present EB613 osteoporosis data at menopause conference
-
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
-
Entera Bio presents oral GLP-2 tablet data at medical conference
-
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
-
Entera Bio presents bone density improvements from EB613 osteoporosis drug
-
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
-
Entera Bio to present clinical data at September medical conferences
-
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
-
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
-
FDA allows Entera Bio to use bone density as primary endpoint for EB613 study
-
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
-
OPKO Health and Entera Bio abstract selected for ESPEN Congress
-
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
-
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
-
OPKO Health (OPK) and Entera Bio (ENTX) Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation
-
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
-
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
-
Entera Bio Ltd. (ENTX) Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis
-
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentatio
-
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
-
OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement
-
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
-
Entera Bio to Participate in Upcoming Events
-
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthr
-
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
-
Entera Bio Ltd. (ENTX) and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin Peptide Tablet Candidate
-
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
